SOUTH SAN FRANCISCO – November 03, 2026 -- IDEAYA Biosciences (Nasdaq: IDYA) completed its first new drug application for darovasertib plus crizotinib in metastatic uveal melanoma during the third quarter, and ended the quarter with $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026. Cash runway guidance into 2030 is unchanged.

Durham – November 02, 2026 -- DPR Construction has appointed Scott Sass, a 27-year company veteran, as business unit leader for Raleigh-Durham, one of its fastest-growing markets.

Sass takes over as Triangle construction employment climbs at one of the fastest rates nationally

Sass steps into the role during a period of significant growth in the Triangle region. Life sciences and healthcare are among DPR's strongest markets there, and both continue to drive demand for skilled construction talent.

TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) plans to begin Phase 1 clinical development of its lead antibody drug conjugate, AKTX-101, in mid-2027, with the compound now moving through IND-enabling toxicology and safety studies and large-scale GMP manufacturing.

CEO Abizer Gaslightwala laid out the strategy in a new CEO Corner segment. He argues that payload differentiation will matter more as ADCs move into front-line therapy and patients develop resistance to current payload classes, leaving few follow-on options.

Las Vegas – September 03, 2026 -- Paralyzed Veterans of America (PVA) opened its 2026 Healthcare Summit + Expo at the Horseshoe Hotel, drawing more than 400 healthcare professionals to advance clinical care for spinal cord injury, MS, and ALS. The event runs through September 2 and features 110 speakers and 60 exhibitors, with remarks from Department of Veterans Affairs Secretary Doug Collins.